<?xml version='1.0' encoding='utf-8'?>
<document id="29992535"><sentence text="Psoriasis and cancer. An Australian/New Zealand narrative." /><sentence text="Patients with psoriasis have an increased risk of cancer, which may be due to impaired immune surveillance, immune modulatory treatments, chronic inflammation and/or co-risk factors such as obesity" /><sentence text=" The increase in treatment-independent solid cancers, including urinary/bladder cancers, oropharynx/larynx, liver/gallbladder and colon/rectal cancers, seem to be linked to alcohol and smoking"><entity charOffset="173-180" id="DDI-PubMed.29992535.s3.e0" text="alcohol" /></sentence><sentence text=" Lung cancer and nonmelanoma skin cancer are also increased in patients with psoriasis" /><sentence text=" The risk of nonmelanoma skin cancer increases with age and severity of psoriasis" /><sentence text=" It is also higher in men, particularly for squamous cell carcinoma, which may reflect previous exposure to PUVA and/or ciclosporin"><entity charOffset="120-131" id="DDI-PubMed.29992535.s6.e0" text="ciclosporin" /></sentence><sentence text=" The risk of cutaneous T-cell lymphoma is substantially higher in patients with moderate-to-severe psoriasis" /><sentence text=" Biologic therapies are independently associated with a slight increase risk of cancer, but this is less than ciclosporin, with the risk confounded by disease severity and other co-risk factors" /><sentence text=" The risk of cancer from low-dose methotrexate is likely minimal"><entity charOffset="34-46" id="DDI-PubMed.29992535.s9.e0" text="methotrexate" /></sentence><sentence text=" In contrast, acitretin is likely protective against a variety of solid and haematological malignancies"><entity charOffset="14-23" id="DDI-PubMed.29992535.s10.e0" text="acitretin" /></sentence><sentence text=" The data on small molecule therapies such as apremilast are too immature for comment, although no signal has yet been identified" /><sentence text=" The decision whether to stop psoriasis immune modulatory treatments following a diagnosis of cancer, and when to resume, needs to be considered in the context of the patients' specific cancer" /><sentence text=" However, there is no absolute need to stop any treatment other than possibly ciclosporin, unless there is a concern over an increased risk of serious infection or drug-drug interaction with cancer-directed therapies, including radiotherapy"><entity charOffset="78-89" id="DDI-PubMed.29992535.s13.e0" text="ciclosporin" /></sentence><sentence text="" /></document>